AstraZeneca PLC (LON:AZN) Given Average Recommendation of “Moderate Buy” by Brokerages

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is £104.12 ($129.35).

Several equities analysts have issued reports on the stock. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($173.91) price objective on shares of AstraZeneca in a research note on Friday, November 22nd.

Insiders Place Their Bets

In other news, insider Tony Mok bought 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of £126.80 ($157.52) per share, for a total transaction of £190,200 ($236,273.29). Also, insider Pascal Soriot bought 20,000 shares of the stock in a transaction on Thursday, November 14th. The shares were acquired at an average price of £102.03 ($126.75) per share, with a total value of £2,040,600 ($2,534,906.83). 0.04% of the stock is owned by corporate insiders.

AstraZeneca Trading Down 0.3 %

Shares of LON:AZN opened at £105.94 ($131.60) on Friday. The company has a market capitalization of £164.21 billion, a PE ratio of 3,363.17, a PEG ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The business has a 50 day moving average of £105.60 and a two-hundred day moving average of £117.18. AstraZeneca has a 12-month low of GBX 9,461 ($117.53) and a 12-month high of £133.88 ($166.31).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.